Skip to main content
Log in

Prediction of future weight change with the dopamine transporter

  • Original Research
  • Published:
Brain Imaging and Behavior Aims and scope Submit manuscript

A Correction to this article was published on 25 April 2023

This article has been updated

Abstract

The brain plays a critical role in controlling and inhibiting pre-potent responses to foods. We investigated the predictive value of dopamine transporter (DAT) availability in the striatum of healthy subjects using 123I-FP-CIT single-photon emission computed tomography (SPECT). In total, 84 participants with available data on their weight for the 60 months after SPECT were included. Specific binding of 123I-FP-CIT to DAT was calculated using region-of-interest analysis, and the putamen-to-caudate nucleus ratio (PCR) was determined. After comparing the weights at 12, 24, 36, 48, and 60 months after SPECT with the baseline weight, we categorized participants into three groups: weight gain (> 5%), stable (−5%–5%), and weight loss (< −5%). PCRs of the weight-loss, stable, and weight-gain groups significantly differed at 36 and 48 months. According to post-hoc analysis, PCRs were lower in the weight gain group at 36 and 48 months compared with at the remaining time points. Overall, our results suggest that PCRs calculated based on DAT availability could be used to predict future weight changes. It is possible that the interactions between the caudate nucleus and the putamen, rather than the individual behavior of each structure, might play an important role in weight regulation. Further studies are needed to investigate the time-dependence of the predictive value of DAT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Change history

References

Download references

Acknowledgements

PPMI, a public–private partnership, is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including abbVie, Avid, Biogen, Bristol-Myers Squibb, COVANCE, GE Healthcare, Genentech, GlaxoSmithKline, Lundbeck, Lilly, Merck, MesoScaleDiscovery, Pfizer, Piramal, Roche, Sanofi Genzyme, Servier, TEVA, and UCB.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kyoungjune Pak.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pak, K., Kim, K., Lee, M.J. et al. Prediction of future weight change with the dopamine transporter. Brain Imaging and Behavior 13, 588–593 (2019). https://doi.org/10.1007/s11682-018-9878-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11682-018-9878-0

Keywords

Navigation